Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

A-040

Supelco

Aminorex solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C9H10N2O
Numero CAS:
2207-50-3
Peso molecolare:
162.19
Codice UNSPSC:
41116107

Grado

certified reference material

Stato

liquid

Caratteristiche

SNAP-N-SPIKE®. SNAP-N-SHOOT®

Confezionamento

ampule of 1 mL

Produttore/marchio commerciale

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

Concentrazione

1.0 mg/mL in acetonitrile

tecniche

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

applicazioni

forensics and toxicology
pharmaceutical (small molecule)

Formato

single component solution

Temperatura di conservazione

−20°C

Stringa SMILE

NC1=NCC(O1)c2ccccc2

InChI

1S/C9H10N2O/c10-9-11-6-8(12-9)7-4-2-1-3-5-7/h1-5,8H,6H2,(H2,10,11)
SYAKTDIEAPMBAL-UHFFFAOYSA-N

Descrizione generale

An analytical reference standard suitable for use in LC/MS or GC/MS methods for clinical toxicology, forensic analysis, urine drug testing, or pharmaceutical research applications. Aminorex is an anorectic stimulant drug and appetite suppressant marketed under the names Menocil and Apiquel®. The drug was retired from the market after it was found to cause pulmonary hypertension.

Note legali

Apiquel is a registered trademark of Puricorp Holdings LLC
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

A-016

(±)-Amphetamine-d11 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-050

Amine Mixture-6 solution, 250 μg/mL each component in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-002

(±)-Amphetamine-d5 (deuterium label on ring) solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-005

(±)-Amphetamine-d5 (deuterium label on side chain) solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-007

(±)-Amphetamine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-008

S(+)-Amphetamine (dextro-Amphetamine) solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-013

(±)-Amphetamine-d5 (deuterium label on side chain) solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-017

(±)-Amphetamine-d8 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-018

(±)-Amphetamine-d8 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-019

(±)-Amphetamine-d11 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-044

(±)-Amphetamine-d6 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-045

(±)-Amphetamine-d6 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-049

R(-)-Amphetamine (levo-Amphetamine), 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

E-018

(±)-N-Ethylamphetamine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

L-026

Lisdexamfetamine dimesylate solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

L-028

Lisdexamfetamine-D4 dimesylate solution, 100 μg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

M-093

(±)-Methamphetamine-D14 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-050

PMA hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

D-122

Diethylpropion-D10 hydrochloride solution, 100 μg/mL in methanol (with 1% 1 M HCl, (as free base)), certified reference material, ampule of 1 mL, Cerilliant®

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Elisabetta Bertol et al.
Journal of pharmaceutical and biomedical analysis, 55(5), 1186-1189 (2011-05-03)
The Drug Enforcement Administration (DEA) reports that as of October 2010, 79% of all cocaine seized in the United States contained levamisole. The equine conversion of levamisole to aminorex has been demonstrated. However, the metabolic fate of levamisole in humans
S P Gaine et al.
Chest, 118(5), 1496-1497 (2000-11-18)
Pulmonary hypertension has been associated with ingestion of the appetite suppressant aminorex. A similar compound, 4-methyl-aminorex (street names, "U-4-E-uh" [pronounced euphoria] or "ice"), is a "designer" drug with central stimulant activity. This drug was discovered on the property of three
Aminorex to fen/phen: an epidemic foretold.
A P Fishman
Circulation, 99(1), 156-161 (1999-01-13)
Richard B Rothman et al.
Annals of the New York Academy of Sciences, 965, 109-126 (2002-07-10)
Several lines of evidence support a dual-deficit model of stimulant withdrawal in which decreases in synaptic dopamine (DA) and serotonin (5-HT) contribute to withdrawal symptoms, drug craving, and relapse. According to the dual-deficit model, DA dysfunction during withdrawal underlies anhedonia
N Sato et al.
Nihon rinsho. Japanese journal of clinical medicine, 59(6), 1197-1202 (2001-06-20)
Primary pulmonary hypertension (PPH) is a rare, often fatal disease that tends to occur with particular frequency in woman. The factors leading to its development remain enigmatic. A variety of toxins and drugs have been implicated in the pathogenesis of
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.